NCT06961617

Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma

Safety and Efficacy of Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Lion TCR Pte. Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a single center and open-label study to determine the safety and efficacy of mRNA HBV-TCR redirected T-cells in HBV-related HCC who are not amenable to/failed conventional treatment.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	LioCyx-M, HBV antigen-specific TCR-redirected T cells	Via intravenous (IV) infusion

Timeline

• Start date: 2024-06-01
• Primary completion: 2027-12-01
• Completion: 2028-12-01
• First posted: 2025-05-08
• Last updated: 2025-05-08

Locations

1 site across 1 country: China